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86 
ABSTRACT IN ENGLISH 87 
In regard to tuberculosis (TB) and other major global epidemics, the use of new diagnostic tests is 88 
increasing dramatically, including in resource-limited countries. Although there has never been as much 89 
digital information generated, this data source has not been exploited to its full potential. In this opinion 90 
paper, we discuss lessons learned from the global scale-up of these laboratory devices and the pathway 91 
to tapping the potential of laboratory-generated information in the field of TB by using connectivity. 92 
Responding to the demand for connectivity, innovative third-party players proposed solutions that have 93 
been widely adopted by field users of the Xpert MTB/RIF assay. The experience associated with the 94 
utilization of these systems, which facilitate the monitoring of wide laboratory networks, stressed the 95 
need for a more global and comprehensive approach to diagnostic connectivity. In addition to 96 
facilitating the reporting of test results, the mobility of digital information allows the sharing of 97 
information generated in programme settings. These data, when they become easily accessible, can be 98 
used to improve patient care, disease surveillance and drug discovery. Therefore they should be 99 
considered as a public health good. We list several examples of concrete initiatives that should allow 100 
data sources to be combined to improve the understanding of the epidemic, support the operational 101 
response, and finally accelerate TB elimination. With the many opportunities that the pooling of data 102 
associated with the TB epidemic can provide, pooling of this information at an international level has 103 
become an absolute priority. 104 
 105 
 106 
 107 
108 
Résumé en Français  109 
Dans le domaine de la tuberculose (TB) et d’autres épidémies majeures au niveau international, 110 
l’utilisation de nouvelles technologies pour le diagnostic s’est largement répandue, y compris dans les 111 
pays à faible ressources. Cependant, malgré la grande quantité de données générées par ces nouveaux 112 
outils, cette source d’information reste aujourd’hui largement inexploitée. Dans cet article d’opinion, 113 
nous discutons les leçons tirées de l’utilisation de ces nouveaux outils diagnostics et certaines pistes 114 
pour mieux mettre à profit, grâce à la connectivité, les informations générées par les laboratoires TB. En 115 
réponse à l’absence de solutions permettant cette  connectivité, des solutions innovantes ont été 116 
proposées par des acteurs tiers et ont été largement adoptées par les utilisateurs du test Xpert 117 
MTB/RIF. L’utilisation croissante de ces solutions qui permettent la surveillance de larges réseaux de 118 
laboratoires a porté l’attention sur la nécessité de proposer une approche plus globale et intégrée par 119 
rapport à la connectivité des laboratoires diagnostiques. Ces solutions facilitent la transmission des 120 
résultats, mais permettent également le partage d’informations générées en situation réelle.  Ces 121 
données, lorsqu’elles deviennent aisément accessibles, peuvent être utilisées pour améliorer la qualité 122 
des soins prodigués aux malades, la surveillance des maladies et la découverte de médicaments. Pour 123 
ces raisons, elles doivent être considérées comme un bien de santé publique. Nous dressons une liste 124 
d’exemples d’initiatives concrètes qui devraient permettre de faciliter le partage de données de 125 
laboratoire dans le but de renforcer notre compréhension de l’épidémie, soutenir les réponses 126 
opérationnelles, et accélérer l´élimination de la TB. En raison des nombreuses opportunités associées au 127 
partage d’information liées à l’épidémie de TB, la centralisation des données au niveau international est 128 
devenue une priorité absolue.  129 
 130 
131 
Resumen en español 132 
En el contexto de la tuberculosis (TB), la utilización de nuevas pruebas diagnósticas está aumentando de 133 
manera espectacular, especialmente en los países en desarrollo. Pese a que nunca se ha generado tanta 134 
cantidad de datos, aún no se aprovechan todas las posibilidades que ofrece esta nueva fuente de 135 
información. En el presente artículo de opinión, se examinan las enseñanzas extraídas del uso en todo el 136 
mundo de estos nuevos instrumentos diagnósticos y se analiza la hoja de ruta hacia la explotación de las 137 
ventajas y el potencial de la conectividad para el diagnóstico de la TB. Respondiendo a la falta de 138 
conectividad incorporada a las herramientas de diagnóstico, se han creado soluciones de conectividad, 139 
que a su vez han sido adoptadas por usuarios en el terreno con el fin de monitorizar la utilización del 140 
test Xpert MTB/RIF. El uso creciente de estas soluciones ha centrado la atención sobre la necesidad de 141 
explorar de manera más general y exhaustiva la conectividad destinada al diagnóstico. Además de 142 
facilitar a los laboratorios la tarea de comunicar los resultados, la información digital debería favorecer 143 
el intercambio y el acopio de la información recogida en el marco programático. Dado que estos datos 144 
pueden mejorar la atención al paciente, la vigilancia de enfermedades y el descubrimiento de nuevos 145 
medicamentos, es preciso considerarlos como un bien de salud pública. Aquí, enumeramos varios 146 
ejemplos de iniciativas concretas que deberían facilitar la combinación de diferentes fuentes de datos 147 
para mejorar la vigilancia de la TB y acelerar su eliminación. Habida cuenta de las múltiples soluciones 148 
que ofrece, la combinación de datos a escala internacional constituye una prioridad absoluta, pues 149 
agilizará el progreso en sectores primordiales como la atención al paciente, la vigilancia epidemiológica 150 
y la respuesta operativa. 151 
152 
Background 153 
In the past decade, the use of new diagnostic tests has increased dramatically in developing 154 
countries’ laboratories and more recently in decentralised point-of-care facilities. Self-contained 155 
molecular diagnostic devices have been successfully deployed to detect tuberculosis (TB) (e.g. 156 
GeneXpert 1) or monitor treatment for HIV (e.g. PIMA 2) in very basic clinical facilities.  157 
Despite the accumulating evidence that these tools can be successfully used in the most challenging 158 
environments3, 4 and the establishment of distribution and funding channels that should theoretically 159 
allow any country to access and scale-up these new technologies,  the majority of patients that could 160 
benefit from these technical evolutions still do not have access to them. It is clear that the 161 
introduction of an improved TB diagnostic is not sufficient for assuring improved outcomes for 162 
patients as the details of implementation within existing health-delivery systems have critical 163 
influence on impact5. We suggest that the introduction of new tools such as GeneXpert offers an 164 
important opportunity to better understand, monitor and improve such delivery systems to assure 165 
greatest impact. If scale-up of novel diagnostic devices can be accompanied by the simultaneous 166 
introduction of up-to-date quality indicators and technical connectivity solutions, the vast amount of 167 
data generated by these new generation of automates could actually both simplify and potentiate 168 
the global response to the TB epidemic.  169 
On a national and global level, the quantity of information produced following the introduction of 170 
new-generation laboratory instruments was not anticipated, thus there were no plans in place for 171 
how to manage the information flow or orient it in such a way that it could generate an evolution in 172 
the organisation of the epidemic response. In the absence of adequate laboratory information 173 
technology infrastructure, complemented with standardised reporting solutions for screening 174 
activities and treatment follow-up, many low-resource countries have continued to use slow and 175 
error-prone paper-based recording systems. In such systems, editing and transmission of paper 176 
reports cause inherent delays and contribute to the cost, complexity and relative inaccuracy of data 177 
interpretation.  178 
Diagnostic ehealth solutions have the potential to help overcome some of these problems and 179 
maximize patient and public health impact following the introduction of a particular technology. The 180 
combination of this unprecedented evolution of the laboratory landscape and the potential of 181 
eHealth could be leveraged to generate evolution in national and global health-delivery systems that 182 
is needed to achieve TB elimination. Pragmatically, this requires device connectivity, wherein testing 183 
data and results are automatically and securely sent to repositories, translated into useful 184 
information and channeled to appropriate parties. Although device connectivity within other 185 
industries has been commonplace for some time, within the healthcare community it is still 186 
considered to be in its infancy 6.  187 
In this paper, we discuss lessons learned from the global scale-up of the first generation of easy-to-188 
connect diagnostic tools 7 and the pathway to tapping the potential of connectivity in the field of TB 189 
diagnostics 8. 190 
 191 
Experience from first-generation connected diagnostics: the example of Xpert MTB/RIF 192 
During the last decade, several diagnostic companies, such as Cepheid Inc. (Sunnyvale, USA) and Alere 193 
Inc. (Waltham, USA), began developing a new generation of tests—essential to fight diseases of poverty 194 
such as TB and HIV—with significant support from public and philanthropic funders including NIH and 195 
BMGF.  196 
The Xpert MTB/RIF, run on the GeneXpert platform, was the first truly game-changing test to come out 197 
of this work and has since been widely distributed in health facilities with limited human and 198 
infrastructure resources. The coverage of GeneXpert varies importantly between countries, with some 199 
countries still having only a couple of machines based in reference laboratories, and other countries 200 
such as South-Africa which rapidly realized the advantages of implementing this novel platform as a 201 
first-line test9. In the last five years, more than 13 million Xpert MTB/RIF tests have been procured 202 
worldwide. When GeneXpert was rolled out in 2010, the instrument had no built-in connectivity outside 203 
basic standards and the TB community did not have the software tools to connect to GeneXpert 204 
machines and optimally use the data being generated. As a consequence, valuable information was 205 
housed in the hard drives of local computers, was never used to inform surveillance efforts or health 206 
care providers, and has largely been lost. 207 
In light of this, national TB programmes called for tools to reduce loss to follow-up and improve device 208 
and laboratory management—including a better ability to maintain cartridge supply and local 209 
redistribution and to evaluate and fulfill the training needs of device operators and lab technicians.  210 
Likewise, TB programmes voiced a need for connectivity systems that could relieve the high overhead 211 
costs of data aggregation and analysis that hamstrings the process of collecting raw data and turning it 212 
into useful information.  213 
In 2012, responding to this critical gap in the implementation landscape, innovative third-party players 214 
developed connectivity solutions. For example, GxAlert (ABT and SystemOne), XpertSMS (Interactive 215 
Research and Development and TB REACH) and GenXchange (Université catholique de Louvain and the 216 
National TB Program of DRC) were devised to respond to the needs of low-resource countries where 217 
often internet is unavailable or unreliable and laboratory information systems or electronic medical 218 
records are not widely used. These tools offered immediate solutions and, based on national requests, 219 
hundreds of local laboratories have since been interconnected by implementing these systems. The 220 
scaling of these connectivity solutions has been taken back by dedicated companies10, 11. 221 
Cepheid, the manufacturer of GeneXpert, also worked to enable remote monitoring of their devices in 222 
response to expressed national needs and requests from the TB community. Like many developers, 223 
Cepheid lacked comprehensive information about what use-cases needed to be supported, and for 224 
ethical and regulatory reasons prioritized data security and confidentiality. As a result, the company 225 
launched an initial software tool that was a step forward but unable to fulfill all programme needs.  226 
In response, a WHO-led alliance of key implementation partners (e.g. USAID, MSF, CHAI and FIND) and 227 
donors (e.g. UNITAID and GFATM) was formed to work with Cepheid to ensure secure, open access to 228 
critical data and to find a broader, holistic approach to connectivity and data management. An 229 
immediate solution was found and both Cepheid and the alliance remain interested in the creation of a 230 
non-proprietary, long-term connectivity platform (or a series of integrated and inter-operational 231 
platforms). This highlights how the global TB community can collectively define priority needs and work 232 
with manufacturers to negotiate and realize solutions for accessing and utilising key data.  233 
Another important lesson from the implementation of first-generation connected diagnostics is the 234 
importance of a well-tailored delivery pathway for connectivity software that supports sustainable up-235 
take in country.  For instance, Alere, the manufacturer of PIMA, devised a country-based public-private 236 
partnership model to ensure appropriate training and support for their connectivity software. Without 237 
this support and engagement of key stakeholders, many countries would have struggled to make use of 238 
the influx of data. While the tool itself has limited wider applicability because of the proprietary nature 239 
of the software, the partnership model offers a valuable example of how non-proprietary, interoperable 240 
systems could be disseminated and nurtured in the future.  241 
Connectivity of diagnostics: a shared responsibility and public health necessity  242 
WHO and research funding agencies have been advocating for, and implementing, data-sharing policies 243 
for some time. While these efforts have increased access to synthesized research data, efforts to make 244 
national programme data available are in their infancy. The use of new generation diagnostic platforms 245 
has triggered thinking about the potential utility of real-time analysis of national data and how 246 
diagnostic connectivity could further improve epidemiological surveillance and guide targeted public 247 
health responses. Accelerated TB elimination, for example, as called for in the WHO End TB strategy 12,  248 
can only be realized if case detection, individual patient management and epidemiological surveillance 249 
are intensified simultaneously, and if these efforts are closely monitored and validated. Data generated 250 
by Xpert MTB/RIF testing can be used both to improve patient management and treatment efforts, and 251 
to provide important population-level information on average infectiousness as a predictor for TB 252 
burden13 and spread of new mutations.  This requires optimized programmatic data management, 253 
pooling, sharing, analysis and use. Realizing improvements in surveillance and public health demands 254 
that information generated by diagnostic technologies in programmatic conditions be easily accessible 255 
and usable for national programmes. Ultimately, data access, enabled by diagnostic connectivity, should 256 
thus be seen as a public health good. Countries, international organizations, test developers and civil 257 
society organizations have a collective responsibility to work together to ensure sustainable use of 258 
information and communications technology to improve healthcare. In doing so, important questions 259 
regarding ethical obligations, data ownership and stakeholder interests, e.g. market competitiveness, 260 
need to be acknowledged and addressed. International collaborative efforts must furthermore address 261 
the issue of personal unique identifiers in a context of continuous human migrations and data mobility.  262 
The way forward: realizing the potential of connected diagnostics 263 
Built-in connectivity has become an evident prerequisite for upcoming diagnostic platforms 14. Tests that 264 
until recently were un-connectable, such as rapid diagnostic tests (e.g. HIV, malaria), can now be 265 
connected to digital readers with results collected, stored and transferred (e.g. Fio Corp, Canada). 266 
In the field of TB diagnostics, a wide range of laboratory tests are used in complementarity. This includes 267 
rapid diagnostic tests and more conventional approaches such as microscopy, culture, drug 268 
susceptibility testing and sequencing 15. Inter-connecting these diagnostic devices and further 269 
integrating this information with clinical indicators is the upcoming challenge for the TB community. 270 
The Connected Diagnostics Initiative (CDx), coordinated by FIND (Geneva, Switzerland), is an example of 271 
a potential solution for accelerating connectivity and interoperability of diagnostic devices. CDx is 272 
providing an open-source software platform allowing for centralised aggregation of data from 273 
diagnostics, regardless of manufacturer. For this new effort to succeed, wide buy-in from implementers, 274 
policymakers and developers will be essential.  In parallel, FIND is working with WHO towards guidelines 275 
for standardised results reporting for diagnostic devices, and assisting developers to be in compliance 276 
with these standards. These efforts go hand in hand with further deployment of local laboratory 277 
information systems and electronic medical records 16. 278 
Alongside this initiative, various groups are creating global databases with the intention of enhancing 279 
research and development applications of data. For instance, genTB (Harvard University) is an open-280 
source platform that allows for the pooling, analysis and visualization of genetic, epidemiological and 281 
clinical data. A global partnership, including WHO, CDC, CPATH, Stop TB, NIAID and FIND, has been 282 
established to develop a data platform (ReSeqTB) to store, curate and provide access to globally 283 
representative TB data that can inform the development of new diagnostics, facilitate clinical decisions 284 
and improve surveillance of drug resistance. While the opportunities for sharing information at an 285 
international scale must be promoted, countries must be provided with technical solutions that can 286 
support them in efficiently managing with whom, and for what purposes, national data are shared, and 287 
to ensure that these database efforts ultimately benefit patients.  288 
Consensus is forming around the central role that connected diagnostics and digitization can play in 289 
tackling health systems weaknesses and diseases of poverty. However, the global health community 290 
must also address complex question of how new tools and practices can be effectively implemented in 291 
health systems. Substantial programmatic changes will be required in countries to absorb the innovation 292 
of connectivity and capture its benefits. This demands a holistic approach to cultivating effective 293 
development and adoption of new diagnostic tools. In this context, laboratory connectivity may serve 294 
the need for more efficient post-marketing surveillance of newly rolled-out diagnostics both for national 295 
stakeholders and their global partners. As the amount of information collected will rapidly increase 296 
beyond our conventional capacities of analysis, the global health community will also need to initiate 297 
and intensify innovative collaborations to exploit the data collected, using big data analysis and self-298 
learning algorithms. Managing, visualizing and analysing such big data creates challenges beyond the 299 
capacities of standard statistical methods, and thus generates an increasing demand for data science 300 
and multidisciplinary efforts. 301 
Conclusion 302 
Our common goal of TB elimination is not a dream anymore: it is an achievable objective with clear 303 
milestones 17. The elimination effort will require a strengthened collaboration between information 304 
technology and big data specialists, social medicine and private companies 6.  305 
In the future, all diagnostic technologies should be inter-connected, allowing data generated by 306 
laboratories to merge in a common repository while safeguarding patient confidentiality.  The TB 307 
community could use such a repository to monitor progress and identify problems and potential 308 
solutions, at both patient and global levels. Data pooling will open up opportunities to comprehend the 309 
rapid evolution of drug-resistant mutations, which will aid in selecting cost-efficient treatment schemes 310 
and improving patient management. With the many solutions it can provide, data pooling at an 311 
international level is an absolute priority, as it will accelerate progress in critical sectors including patient 312 
care, epidemiological surveillance and operational response.  Being an international health emergency, 313 
the TB epidemic requires optimal international collaboration and unambiguous political commitment for 314 
intensifying data sharing efforts. 315 
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